| NCT01144338Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | HbA1c 6.5-10% | Ph 3 | Completed | 629 | Apr 2017 | 18 | results |
| NCT01789957Extension Study for 2993-112 | Exenatide Type 2 diabetes | — | Ph 3 | Completed | 226 | Jun 2004 | — | |
| NCT00717457A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both. | Exenatide, Taspoglutide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 216 | Mar 2011 | 1 | |
| NCT00518115Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only | Albiglutide, Exenatide Type 2 diabetes | BMI 20-40 | Ph 2 | Completed | 163 | May 2008 | 2 | results |
| SUSTAIN™ 3Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes | Exenatide, Semaglutide Type 2 diabetes | HbA1c 7-10.5% | Ph 3 | Completed | 146 | Jul 2015 | 18 | results |
| NCT02229396Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo | Exenatide Type 2 diabetes | HbA1c 8-12% | Ph 3 | Completed | 133 | Apr 2016 | 4 | results |
| NCT00039013Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin | Exenatide Type 2 diabetes | BMI 27-45 | Ph 3 | Completed | 129 | Jun 2003 | 4 | |
| NCT00039026Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea | Exenatide Obesity / overweight, Type 2 diabetes | BMI 27-45 | Ph 3 | Completed | 126 | Aug 2003 | 3 | |
| LEAD-6Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes | Exenatide, Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 125 | Apr 2008 | 16 | results |
| LixiLan-GEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 124 | May 2018 | 5 | results |
| NCT02229383Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus | Exenatide Type 2 diabetes | HbA1c 7.5-12% | Ph 3 | Completed | 123 | Aug 2016 | 2 | results |
| NCT01455857A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Completed | 121 | Aug 2014 | 1 | |
| NCT00359762Exenatide Versus Glimepiride in Patients With Type 2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 3 | Completed | 114 | Mar 2011 | 3 | results |
| DUAL™ IIIThe Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 109 | Mar 2014 | 3 | results |
| NCT01029886Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes | Exenatide, Liraglutide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 108 | Jan 2011 | 2 | results |
| NCT00676338Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) | Exenatide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 106 | Jul 2010 | 5 | results |
| NCT03060980Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 3 | Terminated | 101 | Jan 2018 | — | |
| NCT00035984Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus | Exenatide Obesity / overweight, Type 2 diabetes | BMI 27-45 | Ph 3 | Completed | 100 | Aug 2003 | 3 | |
| NCT00635492CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | — | — | Completed | 96 | Dec 2011 | 2 | results |
| NCT00960661A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 95 | Aug 2012 | 1 | results |
| NCT00082381Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin | Exenatide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 91 | Jul 2008 | 3 | results |
| AWARD-1A Study in Participants With Type 2 Diabetes Mellitus | Dulaglutide, Exenatide Type 2 diabetes | BMI 23-45 | Ph 3 | Completed | 89 | Nov 2011 | 3 | results |
| NCT00641056Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3) | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 75 | May 2009 | 7 | results |
| NCT00082407Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin | Exenatide Type 2 diabetes | BMI 25-40 | Ph 3 | Completed | 69 | Jul 2008 | 3 | results |
| NCT00637273A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2) | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 62 | Feb 2009 | 8 | results |
| NCT04154072A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease | Exenatide Parkinson's disease | — | Ph 2 | Completed | 61 | Feb 2023 | 1 | |
| NCT00111540Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 60 | Sep 2006 | 5 | |
| DURATION-NEO-2Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 60 | Apr 2014 | 2 | results |
| NCT00765817Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 59 | Jan 2010 | 5 | results |
| DURATION-NEO-1Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 58 | Aug 2014 | 2 | results |
| NCT01455870A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 7.5-10.5% | Ph 3 | Completed | 54 | Jul 2015 | — | |
| NCT00658021Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 6.5-10.5% | Ph 3 | Completed | 53 | Apr 2019 | — | results |
| NCT00560417Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide | Exenatide Type 2 diabetes | HbA1c ≥7% | Ph 3 | Completed | 52 | Dec 2009 | — | results |
| NCT00099320Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 51 | Aug 2005 | 2 | |
| NCT01785771A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c | Exenatide Type 2 diabetes | HbA1c 10-12% | Ph 3 | Terminated | 51 | Jan 2018 | 1 | |
| NCT02119819A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 23-45 | Ph 2 | Completed | 51 | Aug 2015 | 1 | results |
| NCT00943917Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 50 | Aug 2010 | 1 | results |
| NCT01060059Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c ≥7% | — | Completed | 50 | May 2012 | — | results |
| NCT01940770Specific Clinical Experience Investigation for Long-term Use of Bydureon. | Exenatide Type 2 diabetes | — | — | Completed | 47 | Nov 2019 | — | |
| NCT01817569Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection) | Exenatide Type 2 diabetes | — | — | Completed | 46 | Oct 2019 | — | |
| NCT00917267A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects | Exenatide Type 2 diabetes | BMI 21-35 | Ph 3 | Completed | 42 | Sep 2010 | 2 | results |
| NCT01455896A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650 | Exenatide Cardiovascular disease, Type 2 diabetes | HbA1c ≥6.5% | Ph 3 | Completed | 42 | Mar 2016 | 2 | |
| NCT00877890A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 41 | Oct 2009 | 5 | results |
| NCT00434954Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-40 | Ph 3 | Completed | 39 | Jun 2009 | 2 | results |
| NCT00870194A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin | Exenatide Type 2 diabetes | BMI 20-45 | Ph 4 | Completed | 36 | Apr 2010 | 1 | results |
| NCT02638805Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide | Exenatide, Liraglutide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 36 | Oct 2017 | — | |
| NCT01554618Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 6.5-11% | Ph 3 | Completed | 35 | May 2020 | 1 | results |
| NCT01003184Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 34 | Jul 2011 | 1 | results |
| IMPERIUMA Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) | Exenatide, Liraglutide Type 2 diabetes | HbA1c 7.3-10.9% | Ph 4 | Terminated | 34 | Oct 2015 | 1 | results |
| NCT00044694Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI 27-45 | Ph 2 | Completed | 33 | May 2003 | 1 | |
| NCT00360334A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients | Exenatide Type 2 diabetes | BMI ≥27 | Ph 3 | Completed | 31 | Apr 2008 | 2 | results |
| NCT02288273Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes. | Exenatide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Completed | 29 | Aug 2015 | — | results |
| NCT00099619Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy | Exenatide Type 2 diabetes | BMI 25-40 | Ph 3 | Completed | 26 | Aug 2005 | 1 | |
| NCT00753896Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 26 | Jul 2009 | 1 | results |
| NCT00308139Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 25 | Jul 2008 | 10 | results |
| NCT00603239Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin | Exenatide Type 2 diabetes | BMI ≤45 | Ph 3 | Completed | 25 | Jul 2009 | 2 | results |
| NCT01147627Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients | Exenatide Type 2 diabetes | BMI ≤10 | Not applicable | Completed | 25 | Aug 2012 | — | results |
| IIH EVOLVEA Trial to Determine the Efficacy and Safety of Presendin in IIH | Exenatide Pseudotumor Cerebri | — | Ph 3 | Terminated | 24 | Sep 2023 | — | results |
| NCT00085969Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | — | Ph 2 | Completed | 23 | Jan 2004 | 1 | |
| NCT00935532Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI 18-35 | Ph 3 | Completed | 22 | Sep 2010 | 2 | results |
| NCT01514149Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy | Exenatide Obesity / overweight, Type 2 diabetes | BMI 27-45 | Ph 2 | Terminated | 22 | May 2012 | — | results |
| NCT00135330An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI 25-40 | Ph 3 | Completed | 19 | Jul 2008 | 2 | results |
| NCT00381342Safety and Efficacy of Exenatide as Monotherapy | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 19 | Sep 2007 | 3 | |
| NCT00477581A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI 25-45 | Ph 4 | Completed | 19 | Sep 2007 | 1 | |
| GETGOAL-XGLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Exenatide, GLP-1 / incretin class catch-all, Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 18 | Nov 2010 | 2 | results |
| NCT00701935Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin | Exenatide Obesity / overweight, Type 2 diabetes | BMI 27-40 | Ph 2 | Terminated | 17 | Jan 2012 | — | results |
| NCT00500370A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients | Exenatide Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 16 | Feb 2008 | 1 | results |
| NCT00359879Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 15 | Jul 2007 | 1 | |
| BydureonA 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients. | Exenatide Type 2 diabetes | — | Ph 4 | Completed | 15 | Dec 2016 | — | results |
| TEXAISTrial of EXenatide in Acute Ischaemic Stroke | Exenatide Stroke | — | Ph 2 | Unknown | 15 | Oct 2021 | 1 | |
| NCT00324363Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin | Exenatide Type 2 diabetes | BMI 21-35 | Ph 3 | Completed | 14 | Apr 2007 | 2 | |
| NCT00382239A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | — | Ph 2 | Completed | 14 | May 2007 | 2 | |
| NCT00516048An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c ≤10.5% | Ph 3 | Completed | 13 | Apr 2008 | — | results |
| NCT00577824Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) | Exenatide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 12 | Nov 2008 | 3 | results |
| FLAT-SUGARFLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) | Exenatide Type 2 diabetes | BMI 25-45 · Established CVD | Ph 4 | Completed | 12 | Jul 2014 | 46 | results |
| CRANIOEXEEfficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy | Exenatide Hypothalamic / syndromic obesity, Obesity / overweight | — | Ph 3 | Completed | 11 | Jun 2018 | 1 | |
| SEVERALSEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | — | Completed | 11 | Nov 2023 | 14 | |
| NCT00375492Effect on Weight Loss of Exenatide Versus Placebo | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-39.9 | Ph 3 | Completed | 10 | Feb 2008 | 1 | results |
| EMPRESExenatide for Myocardial Protection During Reperfusion Study | Exenatide Cardiovascular disease | — | Ph 2 | Unknown | 10 | Jul 2017 | — | |
| EXCEEDA Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs | Exenatide Type 2 diabetes | — | — | Recruiting | 8 | Oct 2026 | — | |
| NCT01928329A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes | Exenatide Type 1 diabetes | HbA1c 6.5-9.5% | Ph 2 | Completed | 8 | Jun 2018 | — | results |
| NCT00103935Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-45 | Ph 2 | Completed | 7 | Oct 2005 | 1 | |
| NCT00516074A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-40 | Ph 3 | Completed | 6 | Apr 2008 | 1 | results |
| COMBAT-MICOMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial | Exenatide Cardiovascular disease | — | Ph 3 | Completed | 6 | Aug 2019 | 5 | |
| GLP-1REWINGLP-1 REceptor Agonists and Real World EvIdeNce | Dulaglutide, Exenatide, Liraglutide, Lixisenatide Type 2 diabetes | — | — | Unknown | 6 | Feb 2019 | 6 | |
| ON TARGET DMComparison of Type 2 Diabetes Pharmacotherapy Regimens | Exenatide, Liraglutide Type 2 diabetes | — | — | Completed | 6 | Dec 2024 | 4 | results |
| NCT00099333Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents | Exenatide Type 2 diabetes | BMI 27-40 | Ph 2 | Completed | 5 | Aug 2005 | 2 | |
| NCT00254254A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | HbA1c 6-11% | Ph 2 | Completed | 5 | Feb 2007 | 1 | |
| NCT02020616A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 23-45 | Ph 1/2 | Terminated | 5 | Feb 2015 | — | results |
| NCT02303730Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes | Exenatide MASH / NAFLD / liver fibrosis, Obesity / overweight, Type 2 diabetes | BMI ≥24 | Ph 4 | Completed | 5 | Nov 2017 | 11 | |
| NCT04269642SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease | Exenatide Parkinson's disease | — | Ph 2 | Unknown | 5 | Sep 2021 | — | |
| BESTMEDBESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Type 2 diabetes | HbA1c 7-11% | — | Unknown | 5 | Jun 2024 | 3 | |
| NCT00806520Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-45 | — | Completed | 5 | Aug 2011 | — | |
| NCT00612794A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 6.5-10% | Ph 1 | Completed | 4 | May 2008 | 1 | |
| NCT00747968The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI 20-45 | Ph 2/3 | Completed | 4 | Nov 2010 | 1 | |
| NCT02320045Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects | Exenatide Healthy volunteers, Renal impairment | BMI 22-40 | Ph 1 | Completed | 4 | Jul 2015 | — | |
| NCT03419624The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients | Exenatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Terminated | 4 | Apr 2019 | 19 | |
| DIRECTGLPDIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c ≥7.5% | Not applicable | Completed | 4 | Jul 2015 | — | |
| NCT00044668Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination | Exenatide Type 2 diabetes | BMI 25-45 | Ph 3 | Completed | 3 | Sep 2005 | 2 | |
| NCT00097500Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 3 | Completed | 3 | Dec 2009 | 5 | results |
| NCT00622323Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients | Exenatide Type 2 diabetes | — | — | Completed | 3 | Sep 2009 | — | |
| NAFLDRole of Exenatide in NASH-a Pilot Study | Exenatide MASH / NAFLD / liver fibrosis, Type 2 diabetes | — | Ph 2/3 | Completed | 3 | Aug 2010 | 11 | results |
| MEXELINHow Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 4 | Completed | 3 | Oct 2009 | — | results |
| NCT00775684Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass | Exenatide Prediabetes / glucose intolerance, Type 2 diabetes | — | Not applicable | Completed | 3 | Nov 2012 | 8 | results |
| EXEPUMPEffects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 2/3 | Unknown | 3 | May 2017 | — | |
| NCT01798264Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c ≥6.5% | Ph 1 | Completed | 3 | May 2009 | 1 | results |
| ECHOEnergy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity | Exenatide, GLP-1 / incretin class catch-all Hypothalamic / syndromic obesity, Obesity / overweight | BMI ≥95 | Ph 3 | Completed | 3 | Mar 2020 | — | results |
| NCT00508287Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 6-10% | Ph 1 | Completed | 3 | Nov 2007 | — | |
| NCT01843127A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes. | Exenatide Type 2 diabetes | BMI 20-40 | Ph 1 | Completed | 3 | Sep 2013 | — | |
| NCT00241423Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-50 | Ph 2 | Completed | 2 | Jun 2007 | 1 | |
| NCT00546728The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes | Exenatide Obesity / overweight, Prediabetes / glucose intolerance | — | Ph 4 | Completed | 2 | Jul 2011 | 1 | results |
| AGREEThe Effects of Exenatide After Gastric Restriction | Efpeglenatide, Exenatide Bariatric Surgery, Obesity / overweight | BMI ≥40 | Ph 2/3 | Unknown | 2 | Dec 2010 | — | |
| NCT01061775Effects of Exenatide on Hypothalamic Obesity | Exenatide Hypothalamic / syndromic obesity, Obesity / overweight | — | Ph 1/2 | Completed | 2 | Jul 2013 | — | results |
| NCT01104701A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension | Exenatide Type 2 diabetes | HbA1c 7.1-11% | Ph 2 | Completed | 2 | Dec 2010 | 1 | results |
| NCT01136798Impact of Exenatide on Sleep in Type 2 Diabetes | Exenatide Type 2 diabetes | — | Not applicable | Completed | 2 | Sep 2016 | — | results |
| NCT01237197Exenatide in Extreme Pediatric Obesity | Exenatide Obesity / overweight | — | Ph 2 | Completed | 2 | May 2012 | 1 | results |
| NCT01297062A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects | Exenatide Healthy volunteers, Obesity / overweight | BMI 25-35 | Ph 1 | Completed | 2 | Apr 2011 | — | results |
| NCT01664624Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes | Exenatide Type 2 diabetes | BMI 23-45 | Ph 1 | Completed | 2 | Nov 2012 | — | results |
| FPSEffects of Obesity Treatments on Food Preferences and Metabolism | Exenatide, Liraglutide Bariatric Surgery Candidate, Obesity / overweight | BMI ≥30 | — | Completed | 2 | Oct 2017 | — | results |
| NCT02455076Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 25-45 | Ph 4 | Completed | 2 | Mar 2018 | 1 | results |
| NCT02793154An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects | Albiglutide, Exenatide Type 2 diabetes | BMI 2-35 | Ph 4 | Terminated | 2 | Mar 2017 | — | results |
| Combat-JUDODouble-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI | Exenatide Obesity / overweight | BMI ≥2 | Ph 2 | Completed | 2 | Sep 2016 | 1 | |
| DRINNLong-acting Exenatide and Cognitive Decline in Dysglycemic Patients | Exenatide Alzheimer's / cognition, Prediabetes / glucose intolerance | HbA1c 5.7-6.4% | Ph 3 | Unknown | 2 | Jul 2019 | 4 | |
| NCT04027023Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus | Exenatide, Liraglutide Type 2 diabetes | HbA1c ≤10% | Ph 4 | Unknown | 2 | Apr 2021 | — | |
| NCT05610800Exenatide for Smoking Cessation and Prevention of Weight Gain | Exenatide Alcohol / substance use, Obesity / overweight | BMI ≥25 | Ph 2 | Completed | 2 | Nov 2025 | 2 | |
| NCT00572689Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes | Exenatide Gestational diabetes | Female | Ph 4 | Withdrawn | 2 | Aug 2015 | — | |
| NCT00672399Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects | Exenatide Healthy volunteers | BMI 19-35 | Ph 1 | Completed | 2 | Jul 2008 | — | |
| NCT01076842Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment | Exenatide Type 2 diabetes | BMI ≤40 | Ph 4 | Completed | 2 | Apr 2011 | — | |
| BCB119Autoinjector Device Assessment Study | Exenatide Healthy volunteers | BMI 22-45 | Ph 1 | Completed | 2 | Dec 2013 | — | |
| NCT02641990Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects | Exenatide Healthy volunteers | BMI 19-32 | Ph 1 | Completed | 2 | Feb 2016 | — | |
| NCT03182192GLP1R-imaging in Hypoglycemia | Exenatide Bariatric Surgery | — | Ph 1 | Unknown | 2 | Jul 2024 | — | |
| NCT03182231GLP1-imaging Before and After Bariatric Surgery | Exenatide Bariatric Surgery, Obesity / overweight, Type 2 diabetes | Female | Ph 1/2 | Unknown | 2 | Jul 2023 | — | |
| INCA-BARIncretin Hormone Antagonism After Bariatric Surgery | Exenatide Bariatric Surgery, Healthy volunteers | — | Not applicable | Completed | 2 | Apr 2021 | — | |
| NCT04159766A Study With NLY01 in Subjects With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 22-35 | Ph 2 | Completed | 2 | Dec 2020 | — | |
| Ver-A-imageA GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass | Exenatide Type 1 diabetes | — | Ph 2 | Unknown | 2 | Apr 2025 | — | |
| NCT01511393An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) | Dulaglutide, Exenatide, Liraglutide, Semaglutide Oncology | — | — | By invitation | 1 | Dec 2039 | 1 | |
| GLORIOUSGLP-1 and Hyperoxia for Organ Protection in Heart Surgery | Exenatide Cardiovascular disease | — | Not applicable | Active, not recruiting | 1 | Sep 2024 | 3 | |
| BASIC2Brain Activation and Satiety in Children 2 | Exenatide, GLP-1 / incretin class catch-all Obesity / overweight | Age 10-12 | Ph 3 | Active, not recruiting | 1 | Aug 2025 | — | |
| CER-4-T2DComparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | — | — | Active, not recruiting | 1 | May 2026 | — | |
| GAPP-SVDGLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) | Exenatide Alzheimer's / cognition | — | Ph 2 | Recruiting | 1 | May 2026 | — | |
| NCT06257966A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin | Dulaglutide, Exenatide Type 2 diabetes | BMI 18.5-35 | Ph 3 | Active, not recruiting | 1 | Oct 2026 | — | |
| NCT06449235Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Not yet recruiting | 1 | Apr 2025 | — | |
| NCT06725693Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease | Exenatide Oncology | — | — | Recruiting | 1 | Nov 2027 | 1 | |
| META-BETAFood (Poly)Phenol Metabotypes and Beta-cell Mass and Function. | Exenatide Healthy volunteers | — | Not applicable | Recruiting | 1 | Dec 2025 | 3 | |
| DASH-CKMHUsing Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, Tirzepatide Metabolic syndrome | — | — | Active, not recruiting | 1 | Jun 2029 | — | |
| ADIPO-CKDClinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Chronic kidney disease, Obesity / overweight, Type 2 diabetes | — | — | Recruiting | 1 | Jul 2027 | 15 | |
| NCT00064714Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes | Exenatide Type 1 diabetes | BMI ≥20 | Ph 2 | Completed | 1 | Mar 2008 | 4 | |
| NCT00254800The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females | Exenatide Healthy volunteers | BMI 19-35 | Ph 1 | Completed | 1 | Aug 2006 | 1 | |
| NCT00313001Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea. | Exenatide Type 2 diabetes | HbA1c ≥8% | Ph 3 | Completed | 1 | Jul 2007 | 1 | |
| NCT00344851Exenatide and Metformin Therapy in Overweight Women With PCOS | Exenatide Obesity / overweight, PCOS | BMI ≥27 | Ph 2 | Completed | 1 | Jun 2007 | 1 | |
| NCT00353834The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c ≥7% | Ph 4 | Completed | 1 | Sep 2010 | — | results |
| NCT00456300Role of Exenatide in Type 1 Diabetes | Exenatide Type 1 diabetes | HbA1c ≤8.5% | Ph 2 | Completed | 1 | Mar 2009 | 1 | results |
| NCT00456885The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women | Exenatide Obesity / overweight, Prediabetes / glucose intolerance | BMI 28-35 | Ph 4 | Completed | 1 | Sep 2010 | 1 | results |
| NCT00529204Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease | Exenatide MASH / NAFLD / liver fibrosis, Obesity / overweight, Type 2 diabetes | BMI ≥35 | Ph 2 | Terminated | 1 | Jul 2009 | 1 | results |
| NCT00551590Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI ≤40 | Ph 1 | Completed | 1 | Dec 2008 | 4 | |
| NCT00566813Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression | Exenatide Type 1 diabetes | — | Ph 1/2 | Completed | 1 | Jul 2010 | 1 | results |
| NCT00569907Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide | Exenatide Type 2 diabetes | HbA1c 7.1-11% | — | Completed | 1 | May 2009 | 4 | |
| NCT00623545Bioenergetic Alterations After Exenatide Administration | Exenatide Obesity / overweight | BMI 30-40 | Ph 4 | Completed | 1 | Apr 2010 | 2 | results |
| NCT00679042Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol | Exenatide Type 1 diabetes | — | Ph 3 | Active, not recruiting | 1 | Jul 2017 | 2 | results |
| NCT00729326Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione | Exenatide Type 2 diabetes | BMI 25-45 | Ph 4 | Completed | 1 | Oct 2009 | — | results |
| NCT00736229Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients | Exenatide Cardiovascular disease, Prediabetes / glucose intolerance | — | Ph 4 | Completed | 1 | Jun 2011 | 1 | results |
| PREDEXPREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide | Exenatide Healthy volunteers | BMI ≤28 | Not applicable | Completed | 1 | Jan 2010 | 1 | |
| NCT00766857Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure | Exenatide Heart failure, Type 2 diabetes | HbA1c 6.5-10% | Ph 4 | Completed | 1 | Dec 2012 | 1 | |
| NCT00799435Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure | Exenatide Heart failure, Type 2 diabetes | — | Ph 4 | Terminated | 1 | Apr 2012 | — | results |
| NCT00835328Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia | Exenatide Prediabetes / glucose intolerance | Age ≤12 | Ph 1/2 | Terminated | 1 | Jan 2017 | — | results |
| POSTCON IIPharmacological Postconditioning to Reduce Infarct Size Following Primary PCI | Exenatide Cardiovascular disease | — | Ph 4 | Completed | 1 | Dec 2009 | 3 | |
| PIO-EXEffect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function | Exenatide Healthy volunteers, Prediabetes / glucose intolerance, Type 2 diabetes | HbA1c ≥7% | Ph 4 | Completed | 1 | Jul 2010 | 1 | results |
| NCT00845507Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults | Exenatide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥30 | Ph 4 | Completed | 1 | Jul 2015 | 1 | results |
| NCT00855439Evaluation of Exenatide in Patients With Diabetic Neuropathy | Exenatide Diabetic neuropathy, Type 2 diabetes | HbA1c ≥7% | Not applicable | Completed | 1 | May 2014 | 1 | results |
| NCT00856609The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects | Exenatide Obesity / overweight | BMI ≥30 | Ph 3 | Completed | 1 | Sep 2016 | 6 | results |
| NCT00882050Intravenous Exenatide (Byetta) During Surgery | Exenatide Perioperative / gastric aspiration risk | — | Ph 1/2 | Completed | 1 | Apr 2016 | — | results |
| NCT00886626GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children | Exenatide Obesity / overweight | — | Ph 2 | Completed | 1 | Feb 2011 | 1 | results |
| NCT00894322A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension | Exenatide Healthy volunteers, Type 2 diabetes | BMI 23-35 | Ph 1/2 | Completed | 1 | Aug 2009 | — | results |
| NCT00937079Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients | Exenatide Oncology | — | — | Completed | 1 | Dec 2011 | 2 | |
| NCT00964262A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide | Exenatide Healthy volunteers | Male · Healthy volunteers | Ph 1 | Completed | 1 | Oct 2010 | 1 | |
| NCT00971659Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 7-10% | Ph 1 | Completed | 1 | Sep 2008 | 1 | |
| NCT00974272Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation | Exenatide Dyslipidemia, Prediabetes / glucose intolerance, Type 2 diabetes | — | Ph 4 | Completed | 1 | Nov 2008 | 2 | |
| NCT01006889Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease | Exenatide MASH / NAFLD / liver fibrosis, Type 2 diabetes | — | Ph 4 | Completed | 1 | Dec 2009 | — | results |
| NCT01046721Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms | Exenatide Healthy volunteers | BMI 20-27 | Not applicable | Completed | 1 | Dec 2012 | 1 | |
| NCT01056549Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans | Exenatide Healthy volunteers | BMI 20-25 | Not applicable | Completed | 1 | Sep 2011 | 1 | |
| NCT01077323A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents | Exenatide Type 2 diabetes | — | — | Completed | 1 | Mar 2008 | — | results |
| NCT01089569Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine | Exenatide Type 2 diabetes | HbA1c ≥7% | Not applicable | Completed | 1 | May 2013 | 2 | results |
| NCT01107717Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM | Exenatide Type 2 diabetes | — | Ph 4 | Completed | 1 | Feb 2023 | 2 | results |
| NCT01154933Exeantide in Type 2 Diabetes on Insulin | Exenatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 2 | Completed | 1 | Nov 2011 | 1 | results |
| NCT01174810Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study | Exenatide Parkinson's disease | — | Ph 2 | Unknown | 1 | Mar 2013 | 1 | |
| NCT01181986The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes | Exenatide Prediabetes / glucose intolerance, Type 2 diabetes | HbA1c ≤8% | Ph 4 | Completed | 1 | Dec 2012 | — | results |
| NCT01208649Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) | Exenatide MASH / NAFLD / liver fibrosis | — | Ph 4 | Completed | 1 | Sep 2010 | — | |
| NCT01235819Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus | Exenatide Type 1 diabetes | — | Ph 4 | Completed | 1 | Sep 2011 | 1 | |
| EXAMIEffect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial) | Exenatide Cardiovascular disease | — | Ph 3 | Unknown | 1 | — | 2 | |
| NCT01255163A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease | Exenatide Alzheimer's / cognition | — | Ph 2 | Terminated | 1 | Nov 2016 | 5 | results |
| NCT01269034New Onset Type 1 Diabetes: Role of Exenatide | Exenatide Healthy volunteers, Type 1 diabetes | Healthy volunteers | Ph 4 | Completed | 1 | Jan 2017 | — | results |
| NCT01269047Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia | Exenatide, Pramlintide Type 1 diabetes | HbA1c ≤9% | Ph 4 | Completed | 1 | Aug 2016 | — | results |
| Braini-ExThe Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes | Exenatide Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI ≤25 | Not applicable | Completed | 1 | Oct 2013 | 1 | |
| SPPSThe Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | HbA1c 7-13% | Ph 2 | Unknown | 1 | Dec 2011 | 1 | |
| ExenatideImpact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes | Exenatide Type 2 diabetes | BMI ≤35 | Not applicable | Completed | 1 | Dec 2014 | — | results |
| ExecutiveGlucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass | Exenatide Cardiovascular disease, Heart failure, Perioperative / gastric aspiration risk | — | Ph 3 | Completed | 1 | May 2014 | 1 | |
| CMBDChanges in Bone Turnover With Exposure to a GLP-1 Receptor Agonist | Exenatide Type 2 diabetes | HbA1c 6.5-9% | Ph 4 | Terminated | 1 | Aug 2015 | — | results |
| NCT01429506Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes | Exenatide Bariatric Surgery Candidate, Obesity / overweight, Type 2 diabetes | BMI ≥27.5 | Not applicable | Completed | 1 | Aug 2012 | — | |
| NCT01432405Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes | Exenatide Type 2 diabetes | — | Ph 4 | Completed | 1 | Jul 2008 | 1 | results |
| NCT01435980Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes | Exenatide Bariatric Surgery Candidate, Obesity / overweight, Type 2 diabetes | BMI ≥35 | Ph 4 | Unknown | 1 | Jan 2016 | — | |
| NCT01444898Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome | Exenatide Hypothalamic / syndromic obesity, Obesity / overweight | — | Not applicable | Completed | 1 | May 2013 | 10 | results |
| NCT01484873Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor | Exenatide Hypothalamic / syndromic obesity, Obesity / overweight | BMI ≥30 | Ph 2 | Completed | 1 | Mar 2015 | 1 | results |
| NCT01501084Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women | Exenatide Healthy volunteers, Obesity / overweight | BMI 19-25 | Ph 1 | Completed | 1 | Dec 2012 | — | |
| NCT01507038Safety and Efficacy of YH14617 in Diabetes Mellitus | Exenatide Type 2 diabetes | BMI ≥23 | Ph 2 | Completed | 1 | Jan 2015 | — | |
| PEPSPharmacology of Exenatide in Pediatric Sepsis | Exenatide | — | Ph 1/2 | Withdrawn | 1 | Oct 2014 | 4 | |
| EMPIREMyocardial Protection of Exenatide in AMI | Exenatide Cardiovascular disease | — | Ph 4 | Completed | 1 | Aug 2011 | 3 | |
| NCT01588418Acute Effect of Exenatide on Brain Glucose Metabolism | Exenatide Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes | BMI 25-40 | Ph 4 | Completed | 1 | Jul 2015 | 2 | results |
| NCT01590433Weight Loss With Exenatide Treatment | Exenatide Obesity / overweight | BMI 28-48 | Ph 4 | Completed | 1 | Jan 2019 | 1 | results |
| NCT01677104The Microvascular Function of GLP-1 and Its Analogues | Exenatide, Liraglutide Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI ≤25 | Not applicable | Completed | 1 | Jul 2014 | 1 | |
| NCT01687582Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients | Exenatide, Liraglutide Psoriasis / psoriatic arthritis, Type 2 diabetes | — | Not applicable | Completed | 1 | Dec 2012 | 2 | |
| PCSAMPhysical and Chemical Study of Atherosclerosis Mechanisms | Exenatide Cardiovascular disease, Dyslipidemia, Hypertension, Metabolic syndrome, Obesity / overweight | — | Ph 4 | Completed | 1 | Dec 2009 | 1 | |
| NCT01744236SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Healthy volunteers, Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 4 | Completed | 1 | Aug 2015 | 6 | |
| NCT01783717Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage | Exenatide Diabetes (other / unspecified), Hypothalamic / syndromic obesity, Obesity / overweight | — | Not applicable | Unknown | 1 | Jan 2015 | — | |
| NCT01791465Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults | Exenatide Diabetes (other / unspecified), HIV | BMI ≥25 | Ph 4 | Terminated | 1 | Dec 2014 | — | results |
| TAOTreatment of Antipsychotic-associated Obesity With a GLP-1 Analogue | Exenatide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥30 | Ph 3 | Completed | 1 | Jun 2015 | 3 | |
| GLP-1-CPOPGLP-1 Receptor Targeting in Diabetic and Healthy Individuals | Exenatide Healthy volunteers, Type 1 diabetes | — | — | Completed | 1 | May 2014 | 1 | |
| NCT01857895Feasibility Study of Exenatide by Continuous Subcutaneous Infusion | Exenatide Healthy volunteers | Healthy volunteers | Ph 1 | Completed | 1 | Nov 2013 | 1 | |
| NCT01951651Effect of Exenatide on Liver and Heart Fat and Inflammation | Exenatide Type 2 diabetes | — | Ph 4 | Completed | 1 | Oct 2012 | — | results |
| ExSTRESSExenatide for Stress Hyperglycemia | Exenatide Cardiovascular disease, Perioperative / gastric aspiration risk | — | Ph 2/3 | Completed | 1 | Dec 2015 | 4 | |
| EXENATIDE-PDTrial of Exenatide for Parkinson's Disease | Exenatide Parkinson's disease | — | Ph 2 | Completed | 1 | May 2016 | 1 | |
| NCT01988545GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow | Exenatide Healthy volunteers | Healthy volunteers | Not applicable | Unknown | 1 | Jun 2014 | — | |
| NCT02042664Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics | Exenatide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Completed | 1 | Jan 2015 | 2 | |
| NCT02057172Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes | Efpeglenatide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 1 | Oct 2014 | 1 | |
| NCT02058940Intravenous Exenatide in Patients With Acute Brain Injury | Exenatide Brain Injuries | — | Ph 4 | Completed | 1 | Aug 2017 | — | results |
| NCT02059564A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus | Efpeglenatide, Exenatide, Liraglutide Type 2 diabetes | BMI 18-45 | Ph 1 | Unknown | 1 | Oct 2014 | 1 | |
| NCT02075281Effect of LAPS-Exendin on Body Weight in Obese Population | Efpeglenatide, Exenatide Obesity / overweight | Healthy volunteers | Ph 2 | Completed | 1 | Jan 2015 | — | |
| NCT02081118Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes | Efpeglenatide, Exenatide Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 1 | Mar 2015 | — | |
| NCT02084251Clinical Trial for PB-119 in Healthy Subjects (Phase I) | Exenatide Healthy volunteers | BMI 19-24 | Ph 1 | Completed | 1 | Nov 2014 | 1 | |
| NCT02090673Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea | Exenatide Type 2 diabetes | — | — | Completed | 1 | Mar 2014 | 1 | |
| SAFEGUARDSafety Evaluation of Adverse Reactions in Diabetes | Exenatide, GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 4 | Completed | 1 | Oct 2015 | — | |
| NCT02104739Effects of Antidiabetic Medications on the Postprandial State in Prediabetes | Exenatide Obesity / overweight, Prediabetes / glucose intolerance | BMI 30-35 | Ph 4 | Completed | 1 | Mar 2017 | 1 | results |
| NCT02118376Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status | Exenatide Obesity / overweight, Type 2 diabetes | Female | Not applicable | Unknown | 1 | Dec 2014 | 1 | |
| NCT02127541New Imaging Procedure for the Localisation of Insulinoma | Exenatide Oncology | — | Not applicable | Completed | 1 | Nov 2017 | 7 | |
| NCT02150707The Differential Effects of Diabetes Therapy on Inflammation | Exenatide, Liraglutide Chronic kidney disease, Type 2 diabetes | — | — | Completed | 1 | Dec 2015 | 4 | |
| APPLELiver and Fat Regulation in Overweight Adolescent Girls | Exenatide Obesity / overweight, PCOS | Female | Ph 2/3 | Completed | 1 | Dec 2022 | 3 | results |
| NCT02160990Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying | Exenatide Obesity / overweight | BMI ≥30 | Ph 4 | Completed | 1 | Mar 2015 | 1 | results |
| NCT02162550Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus | Exenatide Cardiovascular disease, Type 2 diabetes | HbA1c 6.5-10% | Ph 4 | Unknown | 1 | Apr 2019 | 1 | |
| NCT02170324GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men | Exenatide Obesity / overweight | BMI ≥30 | Ph 4 | Completed | 1 | Jul 2015 | — | |
| PREVAILPreserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) | Exenatide Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 1 | Dec 2021 | 1 | |
| NCT02244164Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. | Exenatide, Liraglutide, Lixisenatide Type 2 diabetes | BMI 20-45 | Not applicable | Terminated | 1 | Feb 2023 | 4 | |
| NCT02251431Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome | Exenatide Chronic kidney disease, Type 2 diabetes | HbA1c 6.6-9.9% | Ph 3 | Completed | 1 | Dec 2019 | 7 | results |
| DapalostExploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight | Exenatide Obesity / overweight | BMI 30-45 | Ph 2 | Completed | 1 | Mar 2016 | — | |
| NCT02325960A Comparison of Exenatide and Insulin Glargine | Exenatide Type 2 diabetes | — | Ph 4 | Completed | 1 | Jul 2016 | 1 | |
| NCT02336659Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery | Exenatide Bariatric Surgery | — | Not applicable | Completed | 1 | May 2016 | — | |
| NCT02380521Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Jul 2016 | 6 | |
| NCT02417142Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia | Exenatide Psychiatric (schizophrenia / bipolar / depression) | — | Ph 4 | Completed | 1 | Jul 2019 | — | results |
| ExeQOLImpact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients | Exenatide Cardiovascular disease, Perioperative / gastric aspiration risk | — | Ph 2/3 | Completed | 1 | Jan 2017 | 5 | |
| GLIP1GLP-1 Analogs for Neuroprotection After Cardiac Arrest | Exenatide Brain Injuries, Cardiovascular disease | — | Not applicable | Completed | 1 | Jun 2016 | 4 | |
| NCT02449603Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 21-35 | Ph 4 | Completed | 1 | Apr 2018 | 2 | |
| NCT02456428Incretin-based Drugs and the Risk of Heart Failure | Exenatide, Liraglutide Type 2 diabetes | — | — | Completed | 1 | May 2015 | 1 | |
| NCT02467920Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM | Exenatide Type 2 diabetes | BMI 23-35 | Ph 4 | Completed | 1 | Dec 2017 | — | |
| NCT02475499Incretin-based Drugs and Pancreatic Cancer | Exenatide, Liraglutide Type 2 diabetes | — | — | Completed | 1 | Apr 2015 | 1 | |
| NCT02476760Incretin-based Drugs and Acute Pancreatitis | Exenatide, Liraglutide Type 2 diabetes | — | — | Completed | 1 | Apr 2015 | 1 | |
| NCT02496611Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity | Exenatide Obesity / overweight | Age 12-17 | Ph 2 | Completed | 1 | Aug 2020 | 2 | results |
| EGLIPAThe Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) | Exenatide, Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 4 | Unknown | 1 | Jul 2015 | 3 | |
| RebuildEffects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects | Exenatide Cardiovascular disease, Type 2 diabetes | — | Ph 4 | Completed | 1 | Aug 2022 | 8 | |
| NCT02635386EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | Exenatide Obesity / overweight, PCOS | BMI ≥30 | Ph 3 | Completed | 1 | Jul 2020 | 1 | results |
| GHADDGut Hormones in Obesity, Nicotine and Alcohol Dependence | Exenatide Alcohol / substance use, Obesity / overweight | BMI 28-50 | Early Ph 1 | Unknown | 1 | Aug 2019 | 9 | |
| NCT02802514A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects | Albiglutide, Exenatide Healthy volunteers | Healthy volunteers | Ph 4 | Terminated | 1 | Aug 2017 | — | results |
| DexlarEfficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 4 | Withdrawn | 1 | Jun 2018 | — | |
| EGRABIS1The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke | Exenatide, GLP-1 / incretin class catch-all Stroke | — | Ph 2 | Unknown | 1 | Aug 2023 | — | |
| EGRABINS1The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers | Exenatide, GLP-1 / incretin class catch-all Healthy volunteers | — | Ph 2 | Completed | 1 | Feb 2017 | 1 | |
| NCT02843399Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy | Exenatide Type 2 diabetes | — | — | Completed | 1 | Dec 2016 | — | |
| NCT02844907Regulation of Insulin Secretion by the GLP-1 Receptor | Exenatide Healthy volunteers, Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes | BMI ≤35 | Ph 4 | Terminated | 1 | Dec 2021 | — | results |
| NCT02887625Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM | Exenatide Type 2 diabetes | HbA1c ≥7.5% | Not applicable | Unknown | 1 | May 2017 | 1 | |
| NCT02917057Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment | Exenatide Renal impairment, Type 2 diabetes | — | — | Completed | 1 | Aug 2015 | 1 | |
| NCT02962492An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes | Exenatide Type 1 diabetes | BMI 20-30 | Not applicable | Completed | 1 | Feb 2021 | — | results |
| NCT02975297Exenatide Once Weekly for Smoking Cessation | Exenatide Alcohol / substance use, Obesity / overweight, Prediabetes / glucose intolerance | BMI ≥25 | Ph 1/2 | Completed | 1 | Jan 2020 | 2 | results |
| NCT02981069Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM | Exenatide Type 2 diabetes | BMI 25-35 | Ph 4 | Completed | 1 | Jul 2022 | — | results |
| NCT02987348Clinical Outcomes of Exenatide Versus Basal Insulin | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | — | — | Completed | 1 | Jun 2015 | 1 | |
| exe01Exenatide and Brown Adipose Tissue | Exenatide Healthy volunteers | BMI 18-25 | Ph 4 | Unknown | 1 | Jun 2018 | 1 | |
| EXENDAEffects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus. | Exenatide, GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Nov 2019 | 1 | |
| MAG1CMeal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases | Exenatide Type 1 diabetes | BMI ≥22 | Ph 2 | Completed | 1 | Jun 2019 | 2 | |
| NCT03018665A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese | Exenatide Obesity / overweight, Type 2 diabetes | BMI 24-40 | Ph 4 | Unknown | 1 | Dec 2021 | — | |
| 1981GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes | Exenatide Chronic kidney disease, Type 2 diabetes | HbA1c ≤10% | Ph 4 | Terminated | 1 | Jul 2019 | — | results |
| NCT03151005The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Obesity / overweight, PCOS | BMI ≥24 | Ph 4 | Completed | 1 | Apr 2021 | 12 | results |
| NCT03160261Effect of Exenatide on Cortisol Secretion | Exenatide Healthy volunteers | — | Ph 4 | Completed | 1 | Dec 2017 | 1 | |
| NCT03167411Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection | Exenatide Healthy volunteers | BMI 18-32 | Ph 1 | Completed | 1 | Jun 2017 | — | results |
| EXALTDoes Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence? | Exenatide, GLP-1 / incretin class catch-all Alcohol / substance use, Healthy volunteers | — | Ph 2 | Completed | 1 | Mar 2020 | 1 | |
| NCT03246451The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D | Exenatide Type 2 diabetes | BMI 23-35 | Not applicable | Completed | 1 | Dec 2017 | 1 | |
| NCT03331289Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI 21-45 | Ph 4 | Completed | 1 | Mar 2022 | 1 | results |
| NCT03350191A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients | Exenatide, SAR425899 Obesity / overweight, Type 2 diabetes | BMI 28-38 | Ph 1 | Completed | 1 | Jun 2018 | 1 | |
| NCT03352869Research of Exenatide for Overweight/Obese PCOS Patients With IGR | Exenatide Obesity / overweight, PCOS, Prediabetes / glucose intolerance | Female | Ph 4 | Completed | 1 | Jul 2018 | 8 | |
| DECREASEDECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 | Exenatide Obesity / overweight, Type 2 diabetes | BMI 27-40 | Ph 4 | Completed | 1 | Nov 2019 | 21 | |
| NCT03444142Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes | Dulaglutide, Exenatide Type 2 diabetes | — | Ph 4 | Unknown | 1 | Nov 2021 | — | |
| NCT03492580A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Cardiovascular disease, Type 2 diabetes | Established CVD | — | Completed | 1 | Apr 2018 | — | |
| NCT03645408The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers | Exenatide Alcohol / substance use | — | Ph 1 | Terminated | 1 | Jul 2021 | — | results |
| NCT03671733Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients | Exenatide, Liraglutide Obesity / overweight | BMI ≥28 | Ph 3 | Unknown | 1 | Sep 2022 | — | |
| NLY01-H1A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects | Exenatide Healthy volunteers | BMI 18.5-32 | Ph 1 | Completed | 1 | Jul 2019 | 2 | |
| NCT03804411Prognostic Predictors of Response to Hypoglycemic Therapy | Exenatide, Liraglutide Type 2 diabetes | HbA1c ≤1% | Ph 4 | Unknown | 1 | Mar 2020 | — | |
| COCOAHaemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers | Exenatide Healthy volunteers | BMI 18-30 | Not applicable | Completed | 1 | Nov 2021 | — | |
| GLP1-ex-vivoQuantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin | Exenatide Type 2 diabetes | — | Not applicable | Terminated | 1 | Jun 2021 | 1 | |
| NCT03961256Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation | Exenatide Prediabetes / glucose intolerance, Renal impairment | — | Ph 2 | Completed | 1 | Oct 2021 | — | results |
| NCT04029272Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients | Exenatide Obesity / overweight, PCOS | BMI ≥25 | Ph 4 | Unknown | 1 | Feb 2020 | 2 | |
| NCT04184947Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | — | Completed | 1 | Dec 2018 | 1 | |
| Exenatide-PD3Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease | Exenatide Parkinson's disease | — | Ph 3 | Completed | 1 | Feb 2024 | 2 | |
| NCT04303819The Effect of Exenatide on Fasting Bile Acids | Exenatide Type 2 diabetes | — | — | Completed | 1 | Jan 2020 | 1 | |
| COCONUTEffect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Oct 2022 | — | |
| NCT04347252Glucagon Regulation of Glucose Metabolism | Exenatide Healthy volunteers | HbA1c ≤5.9% | Ph 1 | Completed | 1 | Apr 2021 | — | |
| MSAExenatide Once-weekly as a Treatment for Multiple System Atrophy | Exenatide | — | Ph 2 | Completed | 1 | Mar 2024 | 33 | results |
| PB119Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 1 | Mar 2022 | 1 | |
| NCT04504396Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 1 | Sep 2022 | — | |
| GLP1R-T2DGlucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes | Exenatide Type 2 diabetes | — | Not applicable | Unknown | 1 | Jun 2022 | 1 | |
| FASTExenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia | Exenatide Diabetes (other / unspecified), Prediabetes / glucose intolerance | — | Not applicable | Completed | 1 | Apr 2024 | 1 | |
| NCT04941521Exenatide for Treating Cocaine Use Disorder | Exenatide Alcohol / substance use | — | Ph 1/2 | Completed | 1 | Nov 2021 | 1 | results |
| NCT04969627Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia. | Exenatide Obesity / overweight, PCOS | BMI ≥24 | Ph 4 | Completed | 1 | Jan 2022 | — | |
| NCT05034783[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients | Exenatide Oncology | — | Early Ph 1 | Unknown | 1 | Oct 2022 | 1 | |
| NCT05328843Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function | Exenatide Healthy volunteers, Renal impairment | BMI 18-30 | Ph 1 | Unknown | 1 | Oct 2022 | — | |
| LIBERATE-1Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant | Exenatide, GLP-1 / incretin class catch-all, Semaglutide Healthy volunteers, Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 1 | Aug 2025 | — | |
| NCT05762744Pharmacogenomics of GLP1 Receptor Agonists | Exenatide, GLP-1 / incretin class catch-all Healthy volunteers | BMI 18-40 | Ph 1 | Terminated | 1 | Nov 2018 | 2 | results |
| NCT06247748Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects | Exenatide Healthy volunteers, Obesity / overweight | BMI 24-28 | Ph 1 | Completed | 1 | Apr 2024 | — | |
| NCT00517283A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes | Exenatide Type 2 diabetes | BMI 19-40 | Ph 1 | Completed | 1 | Jun 2005 | — | |
| NCT00551343Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome | Exenatide, GLP-1 / incretin class catch-all Healthy volunteers, Hypothalamic / syndromic obesity | — | Not applicable | Completed | 1 | Sep 2008 | — | |
| ExenatideExenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy | Exenatide Type 2 diabetes | Female | — | Terminated | 1 | Apr 2016 | — | |
| NCT00642538A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus | Exenatide, MKC253 Type 2 diabetes | BMI ≤32 | Ph 1 | Completed | 1 | Sep 2008 | — | |
| NCT00803920Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide | Exenatide Type 2 diabetes | BMI 25-45 | — | Completed | 1 | Feb 2008 | — | |
| NCT00948168Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 4 | Completed | 1 | Jul 2009 | — | |
| T2DMThe Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes | Exenatide, Pramlintide Type 2 diabetes | HbA1c ≤8.5% | Ph 4 | Completed | 1 | May 2011 | — | |
| SR-ExenatideStudy to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects | Exenatide Healthy volunteers | Male · Healthy volunteers | Ph 1 | Completed | 1 | Apr 2012 | — | |
| REACT2The Impact of Food on Blood Sugar in People With Type 2 Diabetes | Exenatide Type 2 diabetes | — | — | Completed | 1 | May 2013 | — | |
| ClosedloopClosed Loop System With Pramlintide Versus Exenatide | Exenatide, Pramlintide Type 1 diabetes | HbA1c ≤8.5% | Ph 1 | Completed | 1 | Jan 2013 | — | |
| NCT01270191The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients | Exenatide Type 2 diabetes | HbA1c 7-9% | Ph 4 | Unknown | 1 | Dec 2014 | — | |
| NCT01416649Impact of Exenatide on Sleep Duration | Exenatide Type 2 diabetes | — | — | Completed | 1 | Apr 2021 | — | |
| NCT01452451Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus | Efpeglenatide, Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | HbA1c 7-10% | Ph 2 | Completed | 1 | Jun 2013 | — | |
| NCT01455883A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 7.5-10.5% | Ph 3 | Withdrawn | 1 | Jul 2014 | — | |
| NCT01455909A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Withdrawn | 1 | Jul 2014 | — | |
| NCT01455922A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes | Exenatide Type 2 diabetes | HbA1c 7.5-10.5% | Ph 3 | Withdrawn | 1 | Jul 2014 | — | |
| AGAC2Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients | Exenatide Type 2 diabetes | HbA1c 8-12% | Not applicable | Completed | 1 | Jun 2013 | — | |
| NCT01776788Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients | Exenatide Type 2 diabetes | BMI ≤10 | Ph 4 | Completed | 1 | Feb 2015 | — | |
| NCT01855490Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes | Exenatide Type 1 diabetes | — | Ph 1 | Completed | 1 | Jul 2013 | — | |
| NCT01876849An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | — | Ph 3 | Completed | 1 | Jul 2008 | — | |
| NCT01934816Incretin and KATP Channels | Exenatide, Liraglutide Healthy volunteers | BMI ≤25 | Not applicable | Terminated | 1 | Jan 2015 | — | |
| T2DMRSEffect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy | Exenatide Type 2 diabetes | BMI ≥3 | Ph 4 | Unknown | 1 | Jun 2015 | — | |
| NCT02302976GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration | Exenatide Alcohol / substance use | — | Ph 1 | Completed | 1 | Aug 2018 | — | |
| NCT0256037668Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis | Exenatide Oncology | — | Early Ph 1 | Unknown | 1 | Dec 2016 | — | |
| NCT02641899Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs | Exenatide Healthy volunteers | BMI 19-32 | Ph 1 | Completed | 1 | Mar 2016 | — | |
| NCT02650479Study of the Effects of Intravenous Exenatide on Cardiac Repolarization | Exenatide Healthy volunteers | BMI 19-35 | Ph 1 | Completed | 1 | Apr 2016 | — | |
| NCT02685852Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia | Exenatide Bariatric Surgery | — | Ph 1 | Completed | 1 | Jul 2019 | — | |
| NCT02735031Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes | Exenatide, GLP-1 / incretin class catch-all Type 1 diabetes | — | Ph 2/3 | Completed | 1 | Mar 2018 | — | |
| NCT02974244Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins | Exenatide Type 2 diabetes | — | — | Completed | 1 | Oct 2014 | — | |
| NCT03059719Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | — | Ph 1 | Completed | 1 | Sep 2016 | — | |
| NCT03182296Visualizing Beta Cells in Patients With a History of Gestational Diabetes | Exenatide Gestational diabetes, Healthy volunteers | BMI 17-30 | Not applicable | Unknown | 1 | Jan 2026 | — | |
| NCT03199261A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects | Exenatide Healthy volunteers | BMI 19-26 | Ph 1 | Completed | 1 | Jan 2017 | — | |
| PCOSResearch of Intensive Metabolic Intervention Before Pregnancy in PCOS | Exenatide PCOS, Prediabetes / glucose intolerance | Female | Ph 4 | Unknown | 1 | Dec 2018 | — | |
| NCT03456687Effects of Exenatide on Motor Function and the Brain | Exenatide Parkinson's disease | — | Ph 1 | Completed | 1 | Oct 2020 | — | |
| GLP-1-CHIGLP-1 Receptor Expression in CHI | Exenatide Prediabetes / glucose intolerance | Age ≤16 | — | Unknown | 1 | Feb 2019 | — | |
| iPAVEImaging Pituitary ActiVation by Exendin | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | — | Not applicable | Completed | 1 | Apr 2024 | — | |
| NCT03970044Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept. | Exenatide Type 2 diabetes | BMI ≤45 | Ph 4 | Completed | 1 | Jun 2021 | — | |
| NCT04185350Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma | Exenatide Oncology | — | Early Ph 1 | Unknown | 1 | Apr 2020 | — | |
| NCT04305002Exenatide Treatment in Parkinson's Disease | Exenatide Parkinson's disease | — | Ph 2 | Unknown | 1 | Oct 2023 | — | |
| NCT04379856Proof of Concept Study in Patients With Short Bowel Syndrome | Exenatide Gastrointestinal (gastroparesis / short bowel / pancreatitis) | — | Ph 1/2 | Unknown | 1 | Dec 2020 | — | |
| NCT04897802Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) | Exenatide Healthy volunteers | Healthy volunteers | Ph 4 | Completed | 1 | Apr 2024 | — | |
| NCT04979611The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma | Exenatide Oncology | — | Ph 1 | Unknown | 1 | Aug 2025 | — | |
| ENTRAPExendin PET/CT for Imaging of Paragangliomas | Exenatide Oncology | — | — | Unknown | 1 | Dec 2024 | — | |
| NCT05482789Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes | Exenatide Gestational diabetes | Female | Ph 4 | Recruiting | 1 | Dec 2025 | — | |
| BetaFITBetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation | Exenatide Type 1 diabetes | BMI 18-30 | Ph 2 | Unknown | 1 | Feb 2024 | — | |
| NCT05662189Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus | Exenatide Healthy volunteers, Prediabetes / glucose intolerance, Type 1 diabetes, Type 2 diabetes | — | Not applicable | Recruiting | 1 | Jul 2025 | — | |
| NCT06252623Exenatide For Reducing the Reinforcing Effects of Cocaine | Exenatide Alcohol / substance use | — | Ph 1 | Withdrawn | 1 | Mar 2026 | — | |
| NCT06254014A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients | Exenatide Type 2 diabetes | BMI 18.5-35 | Ph 3 | Active, not recruiting | 1 | May 2026 | — | |
| NCT06256419Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | BMI 20-35 | Not applicable | Recruiting | 1 | Jan 2028 | — | |
| NCT07340437Clinical Study of 18F-Exendin-4 in Insulinoma | Exenatide Oncology | — | — | Completed | 1 | Oct 2025 | — | |
| CR059101A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI ≤40 | Early Ph 1 | Recruiting | 1 | Aug 2026 | — | |
| TAG-MSTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis | Exenatide Multiple sclerosis, Obesity / overweight | BMI ≥27 | Ph 2 | Recruiting | 1 | Jan 2030 | — | |
| NCT00782418A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED) | Exenatide Healthy volunteers | BMI ≤26 | Ph 1 | Completed | 0 | Feb 2009 | 1 | results |
| NCT00845559The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults | Exenatide Healthy volunteers, Obesity / overweight, Prediabetes / glucose intolerance | BMI ≥97 | Ph 4 | Withdrawn | 0 | Mar 2010 | — | |
| NCT01302327GLP Analogs for Diabetes in Wolfram Syndrome Patients | Exenatide Wolfram Syndrome | — | Not applicable | Withdrawn | 0 | Mar 2013 | 1 | |
| NCT02084654Exenatide and Weight Loss for Diabetes Prevention | Exenatide Obesity / overweight, Prediabetes / glucose intolerance | BMI 27-37 | Ph 1 | Completed | 0 | Oct 2012 | — | |
| NCT02344641Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients | Exenatide Heart failure, Type 2 diabetes | HbA1c 7-10% | Not applicable | Unknown | 0 | Dec 2016 | — | |
| GLP1-EX-GELOEffect of Gelofusine on GLP1-receptor Imaging | Exenatide Healthy volunteers | BMI ≥30 | Ph 1/2 | Completed | 0 | May 2017 | — | |
| NCT02584075Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function | Exenatide Obesity / overweight, Type 2 diabetes | BMI ≥25 | Ph 4 | Unknown | 0 | Nov 2017 | — | |
| DIPITDiabetes Islet Preservation Immune Treatment | Exenatide Type 1 diabetes | — | Ph 1/2 | Withdrawn | 0 | Jun 2024 | 2 | |
| NCT02690883Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy | Exenatide Chronic kidney disease, Type 2 diabetes | BMI 18-35 | Ph 4 | Completed | 0 | Dec 2019 | 17 | |
| NCT03239119The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI ≤35 | Ph 3 | Unknown | 0 | Dec 2018 | — | |
| NCT03297879Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes | Exenatide Obesity / overweight, Type 2 diabetes | BMI ≥24 | Ph 4 | Completed | 0 | Feb 2016 | 2 | |
| NCT04001231Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus | Exenatide Type 2 diabetes | BMI 18.5-35 | Ph 1 | Withdrawn | 0 | Jul 2021 | — | |
| NCT00259896In-patient Study in Patients With Type 2 Diabetes Mellitus | Exenatide Healthy volunteers, Type 2 diabetes | — | Ph 1 | Completed | 0 | — | — | |
| NCT01021527A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED) | Exenatide Healthy volunteers | Male | Ph 1 | Completed | 0 | Mar 2008 | — | |
| NCT01093729A Study of HM11260C in Healthy Male Subject | Efpeglenatide, Exenatide Healthy volunteers | BMI 18-27 | Ph 1 | Completed | 0 | Oct 2010 | — | |
| NCT01602913Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine | Exenatide, Liraglutide | — | — | Completed | 0 | May 2012 | — | |
| NCT01767389Glucagon-like Peptide (GLP) Utilization and Safety | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | — | — | Completed | 0 | Dec 2013 | — | |
| NCT01818648Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome | Exenatide Gastrointestinal (gastroparesis / short bowel / pancreatitis) | — | Ph 4 | Withdrawn | 0 | Jan 2014 | — | |
| ALFA-1The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 1 diabetes | — | Ph 2/3 | Unknown | 0 | Nov 2015 | — | |
| NCT02895672GLP-1/Basal Insulin Combination Therapy | Exenatide, Liraglutide Type 2 diabetes | — | — | Completed | 0 | Nov 2016 | — | |
| GLP-1-AHH68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH | Exenatide Oncology | — | Ph 1/2 | Completed | 0 | Jan 2021 | — | |
